Effectiveness and safety of target-specific RNA-based lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials.
Jordan Steven Widjaja, Arga Setyo Adji, Aufa Baraja et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis of randomized controlled trials assessed the efficacy and safety of RNA-based therapies targeting PCSK9, APOC3, or ANGPTL3 in patients with hyperlipidemia or hypertriglyceridemia. Across 16 trials involving 5604 participants, effects differed by molecular target: PCSK9-targeting therapy produced the largest reductions in LDL-C, ApoB, and non-HDL-C, while APOC3-targeting therapies produced the largest triglyceride reduction (MD -52.26%, 95% CI -56.50 to -48.02). Overall adverse-event measures were comparable with placebo; long-term clinical outcome data remain limited.
Key findings
- PCSK9-targeting therapy reduced LDL-C by MD -53.01% (95% CI -57.56 to -48.45), the largest reduction among the target groups.
- PCSK9-targeting therapy produced the greatest reductions in ApoB (MD -39.59%, 95% CI -43.33 to -35.85) and non-HDL-C (MD -44.62%, 95% CI -47.73 to -41.51).
- APOC3-targeting therapies produced the greatest triglyceride reduction (MD -52.26%, 95% CI -56.50 to -48.02).
- Total and serious adverse events, and events leading to treatment discontinuation, were comparable between RNA-based therapies and placebo.
Why it matters
The findings show that RNA-based lipid-lowering therapies have distinct lipid effects according to their molecular target, which helps clarify what each approach may lower most effectively. The pooled safety measures were comparable with placebo, but lipid changes do not establish long-term clinical benefit. Limited long-term outcome data and differences in individual adverse outcomes leave important questions for further study.
What to keep in mind
Long-term clinical outcome data were limited, and the abstract notes differences in individual adverse outcomes requiring further investigation.